Your browser doesn't support javascript.
loading
Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.
Yoon, Meesun; Lee, Hyo Kyung; Park, Eun Young; Kim, Jin Hee; Lee, Jong Hoon; Kim, Young Seok; Kim, Hak Jae; Kim, Hunjung; Yoo, Chong Woo; Lee, Sun; Hong, Eun Kyung; Kim, Tae Hyun; Kim, Tae-Sung; Seo, Sang-Soo; Kang, Sokbom; Chang, Suk-Joon; Shin, Hye Jin; Uong, Tung Nguyen Thanh; Lee, Semin; Kim, Joo-Young.
Afiliação
  • Yoon M; Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, South Korea.
  • Lee HK; Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan, South Korea.
  • Park EY; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Kim JH; Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
  • Lee JH; Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Seoul, South Korea.
  • Kim YS; Department of Radiation Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea.
  • Kim HJ; Department of Radiation Oncology, Seoul National University, College of Medicine, Seoul, South Korea.
  • Kim H; Department of Radiation Oncology, Inha University Hospital, Inha University, School of Medicine, Incheon, South Korea.
  • Yoo CW; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Lee S; Department of Pathology, College of Medicine, Kyung Hee University, Seoul, South Korea.
  • Hong EK; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Kim TH; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Kim TS; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Seo SS; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Kang S; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Chang SJ; Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, South Korea.
  • Shin HJ; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
  • Uong TNT; Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, South Korea.
  • Lee S; Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan, South Korea.
  • Kim JY; Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
Int J Cancer ; 151(12): 2182-2194, 2022 Dec 15.
Article em En | MEDLINE | ID: mdl-35751421
ABSTRACT
We conducted a prospective phase II study on whether extended-field irradiation (EFI) confers survival benefits depending on hypoxic markers in locally advanced uterine cervical cancer (LAUCC). RNA-seq was performed to identify immune and hypoxic gene signatures. A total of 288 patients were randomized to either EFI or pelvic radiotherapy (PRT). All patients completed chemoradiotherapy. Overall, significantly higher 5-year para-aortic recurrence free survival (PARFS) rate occurred in EFI (97.6%) than in PRT group (87.2%), with marginal tendency to improve disease-free survival (DFS; 78% vs 70%, P = .066). Subgroup analyses were performed based on carbonic anhydrase 9 (CA9)-only positive, CA9/hypoxia-inducible factor (HIF) double positive and CA9 negative. In the CA9-only positive, EFI successfully increased 5-year PARFS (100% vs 76.4%, P = .010), resulting in significantly improved long-term DFS (85.7% vs 54.7%, P = .023) compared to the PRT, while there was no such benefit of EFI in the CA9/HIFs double positive. RNA-seq analysis identified distinct immunehigh subgroup with negative correlation with hypoxia gene signatures (R = -.37, P < .01), which showed a higher 5-year DFS than the immunelow (P = .032). Hypoxia-related genes were upregulated in the CA9/HIFs double positive compared to CA9 negative (P < .05). Only 17.4% of patients in CA9-negative group showed immunelow signatures, while 40.0% of patients in the double-positive group exhibited immunelow signatures. In conclusion, EFI improved PARFS significantly in all patients, but therapeutic efficacy of EFI in terms of improved DFS was solely observed in CA9-only positive LAUCC, and not in CA9/HIFs double-positive subgroup. RNA-seq analysis suggested that hypoxia-induced immunosuppression may be related to treatment resistance in LAUCC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero Idioma: En Ano de publicação: 2022 Tipo de documento: Article